Guillermina G. M.
- Country
- Spain
- Department
- Neurology
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Phase 2a Randomized Double‑Blind Placebo‑Controlled Study of Empasiprubart IV Monotherapy in AChR‑Ab Seropositive Generalized Myasthenia Gravis
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Iptacopan in Patients with Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 33 of 102 partner sites.
Specializations
Neurology & Neuroinflammation
The investigator specializes in studying chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on innovative therapeutic approaches for this neurological condition.
- Autoimmune Neuropathies
- Neurological Disorders
- Inflammatory Conditions
Their research encompasses the evaluation of novel treatments targeting nerve inflammation and demyelination processes.
Therapeutic Development
The investigator conducts research in emerging therapeutic solutions for neurological disorders, with particular attention to safety and tolerability assessments.
- Novel Treatment Evaluation
- Safety Assessment
- Clinical Efficacy Studies
Their work involves investigating new compounds for treating autoimmune neurological conditions.
Clinical Management
The investigator focuses on treatment optimization for patients with chronic neurological conditions, emphasizing long-term therapeutic outcomes.
- Patient Safety Monitoring
- Treatment Response Assessment
- Disease Management Strategies
Their expertise extends to evaluating therapeutic interventions for chronic inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.